Alpha DNA Investment Management’s Criteo CRTO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-12,541
Closed -$473K 214
2024
Q2
$473K Buy
+12,541
New +$459K 0.18% 121
2022
Q1
Sell
-40,440
Closed -$1.57M 126
2021
Q4
$1.57M Buy
40,440
+1,509
+4% +$58K 0.99% 48
2021
Q3
$1.43M Buy
+38,931
New +$1.5M 0.97% 49
2021
Q2
Sell
-87
Closed -$3K 214
2021
Q1
$3K Buy
+87
New +$2.39K ﹤0.01% 461

Other funds holding CRTO

Alpha DNA Investment Management's CRTO Position: Q3 2024 in Review

Alpha DNA Investment Management sold out of Criteo (CRTO) in Q3 2024, closing a stake of 12,541 shares — an estimated $473K sold.

Alpha DNA Investment Management first reported a position in CRTO in Q1 2021 and held it in 4 quarters. The position peaked at $1.57M in Q4 2021. 176 funds tracked by Wall St. Rank hold CRTO as of Q3 2024.

  • Alpha DNA Investment Management reported no remaining Criteo position as of Q3 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 12,541 Criteo shares in Q3 2024, an estimated $473K.
  • Alpha DNA Investment Management first reported a position in Criteo in Q1 2021 and held it in 4 quarters.
  • Alpha DNA Investment Management's Criteo position peaked at $1.57M in Q4 2021.
  • 176 funds tracked by Wall St. Rank held Criteo as of Q3 2024.

Based on Alpha DNA Investment Management's 13F filing for Q3 2024, filed 12 Nov 2024.